AWARD NUMBER: W81XWH-12-1-0195

TITLE: Targeting the Ron-DEK Signaling Axis in Breast Cancer

PRINCIPAL INVESTIGATORS:

Dr. Susan Waltz

CONTRACTING ORGANIZATION:

University of Cincinnati
Cincinnati, OH 45267-0529

REPORT DATE:

September 2014

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
                         Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                                    Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE September 2014	2. REPORT TYPE Annual	3. DATES COVERED 1 Sep 2013 - 31 Aug 2014

4. TITLE AND SUBTITLE
Targeting the Ron-DEK Signaling Axis in Breast Cancer

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-12-1-0195

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Dr. Susan Waltz

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

E-Mail: susan.waltz@uc.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Cincinnati
Cincinnati, OH 45267-0529

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT

The Ron receptor tyrosine kinase is over-expressed and over-activated in a cohort of human cancers, with the most compelling data yet found in breast cancer. Specifically, Ron is overexpressed in approximately 50% of human breast cancers, and has been shown to be an independent predictor of both metastases and poor prognosis in women with this disease. While Ron overexpression appears to be an important factor in human breast cancer growth and metastasis, a significant gap exists in our knowledge about the signaling pathways that Ron activates in breast tumors, and about the importance of these pathways with respect to overall tumor growth and metastatic dissemination. Our laboratories have shown that mammary tumors from mice overexpressing Ron selectively in the mammary epithelium exhibit increased levels of the DEK proto-oncogene. In addition, we also show that ligand-induced Ron activation in human and murine breast cancer cell lines induces the accumulation of DEK protein. This accumulation of DEK is significant as DEK overexpression in breast cancer cell lines leads to increases in cell growth and migration while DEK depletion in breast cancer cells leads to dramatic reductions in cell growth and migration. Moreover, we also show that DEK deficient cells are more susceptible to DNA damage. Based on these data, our goal is to test the *hypothesis that Ron-mediated DEK upregulation contributes functionally to breast cancer development, dissemination and resistance to clastogenic therapies and that targeting the Ron-DEK signaling axis may represent an important new therapeutic option for the treatment of breast cancer.* To test this hypothesis, **two Specific Aims** were proposed. In Aim 1, we will determine the requirement of DEK in Ron overexpressing breast cancers utilizing a combination of DEK loss of function and Ron transgenic overexpression. Aim 2 will examine the therapeutic utility of targeting Ron and DEK on beta-catenin activation and breast cancer growth. The proposed studies are uniquely innovative in many aspects. First, the experiments involve a new murine model of aggressive breast cancer that was developed in the Waltz laboratory, which mimics Ron overexpression observed in human patients. Second, we are using a new DEK knockout mouse model that was characterized and recently reported by the Wells laboratory. Third, the role of DEK in Ron-driven breast cancer, alone or in combination with chemotherapy has not been tested. Fourth, directly assessing the involvement of the Ron-DEK axis in breast cancer is a novel idea as it is unknown if DEK loss will reduce local tumor growth and/or the incidence of metastasis in a relevant *in vivo* system of breast tumorigenesis. Thus, we feel the new connection of the Ron-DEK signaling pathway and Ron/DEK as therapeutic targets represents a highly innovative area of study which may have an enormous impact on future diagnosis and treatment of patients with breast cancer.

15. SUBJECT TERMS

Ron receptor, Dek, beta-catenin, breast cancer

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	**b. ABSTRACT**	**c. THIS PAGE**	U	23	19b. TELEPHONE NUMBER *(include area code)*
U	U	U			

Table of Contents

INTRODUCTION

The overall goal of our study to is test the hypothesis that Ron-mediated DEK upregulation contributes functionally to breast cancer development, dissemination and resistance to clastogenic therapies and that targeting the Ron-DEK signaling axis may represent an important new therapeutic option for the treatment of breast cancer.

KEY WORDS

Ron receptor, Dek, beta-catenin, breast cancer

BODY

To meet the goals of this study, two Tasks were outlined in the approved Statement of Work.

Task 1: Determine the functional significance of DEK expression in Ron-driven breast tumorigenesis and tumor response to chemotherapy.

Task 2: Examine the therapeutic utility of targeting Ron and DEK on beta-catenin activation and breast cancer growth.

Task 1
Task 1 was split into two main objectives. The first objective was to define the role of Dek in Ron-driven tumorigenesis, which was the focal point of work in Year 1. We have recently submitted and published a manuscript on the work in this task (1). This manuscript is appended to the current application. To summarize, this report identified two commonly overexpressed breast cancer oncogenes, Ron and DEK in the cooperation and promotion of advanced breast cancer through multipronged effects on beta-catenin signaling. We demonstrated that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the clinically relevant murine model of breast cancer driven by mammary specific Ron overexpression (MMTV-Ron mice) led to a significant delay in breast tumor development, characterized by decreased cell proliferation, diminished metastasis and fewer cells expressing mammary cancer stem cell markers. Dek expression stimulated the production and secretion of Wnt ligands to sustain an autocrine/paracrine canonical beta-catenin signaling loop. Finally, our data showed that Dek overexpression promoted tumorigenic properties in immortalized human mammary epithelial MCF10A cells and in the context of Ron receptor activation, correlated with disease recurrence and metastasis in patients. The results of these studies showed that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/beta-catenin signaling. (Initiating and Partnering PIs)

The following is a summary of new data generated in the last funding period and the significance of the study implications:

Dek loss reduces metastatic burden and enhances invasiveness of breast cancer.
Previous reports using in vitro transwell assays suggest that DEK conferred invasive potential to breast cancer cells via a β-catenin dependent mechanism (2). However, an association between DEK expression and metastatic events in vivo had not yet been investigated. We examined metastases to the lungs and liver from MMTV-Ron Dek−/− and MMTV-Ron Dek+/+ mice. Of the mice examined, 100% of MMTV-Ron Dek+/+ and 83% of MMTV-Ron Dek−/− mice developed liver metastases. All MMTV-Ron mice examined had lung metastases, but MMTV-Ron Dek+/+ mice had more than double the number of lung metastases per animal when compared with MMTV-Ron Dek−/− mice (**Figure 1a**). Lung metastases were positive for cytokeratin 5 staining, indicating they were epithelial in origin (data not shown). One potential mechanism of metastasis is through the expression of matrix metalloproteases (MMPs), including the Wnt targets MMP2 and MMP9 (3). Primary and xenograft tumors and the cell lines showed no correlation between DEK expression and MMP2 or MMP9 expression (data not shown). To test invasion in vitro, Dek-proficient and -deficient cell lines obtained from mammary tumors of MMTV-Ron Dek+/+ and Dek-/- mice respectively, were analyzed using Matrigel

transwell invasion assays. Dek expression enhanced the invasive potential in all cell lines tested (**Figure 1b**). In an analysis of Dek proficient and deficient cells from these models, we further showed that Dek expression differentially regulates Wnt4, Wnt7b and Wnt10b.   (Partnering PI)


Figure 1. Dek expression supports breast cancer metastasis in vivo and in vitro. (a) MMTV-Ron Dek+/+ mice have a greater metastatic lung tumor burden than MMTV-Ron Dek−/− mice. Lungs were harvested from six MMTV-Ron Dek−/− and five MMTV-Ron Dek+/+ mice with similar primary tumor volumes for the largest tumor and serial sections were microscopically analyzed for tumor metastases. Total tumor burden from all lung sections in wildtype mice was 18.38±1.754 compared with 8.183±1.661 in knockout mice (P=0.0023, unpaired two-tailed t-test). The average number of lung metastases per mouse is quantified and a representative hematoxylin and eosin staining from each genotype is depicted below. Black arrows highlight metastatic tumors within the lungs. (b) Dek expression correlates with cellular invasion in vitro. MMTV-Ron Dek+/+ cell lines (R7 and RD258) transduced with Deksh ('+Deksh') or NTsh control, and MMTV-Ron Dek−/− cell lines (RD147, RD219, RD238 and RD271) transduced with an mDek construct ('+mDek') or control R780 vector were subjected to Matrigel transwell assays. Data are represented as fold change compared with the respective control for each cell line (NTsh or R780) for triplicate experiments. Significance was calculated with a one-tailed unpaired t-test.

Ron receptor activation increases Dek expression and Dek overexpression confers tumorigenic phenotypes to immortalized mammary epithelial cells (MECs)

To examine associations of Dek downstream of Ron activation, we treated T47D cells with HGFL. DEK mRNA was upregulated within hours of HGFL stimulation, resulting in elevated protein levels (**Figures 2a** and **b**). This further supports the hypothesis that DEK overexpression in breast cancer cell lines is induced by Ron receptor activation. To determine if DEK overexpression promoted tumorigenic phenotypes in human mammary cells similar to that observed in the mouse, we used 3D cultures of MCF10A immortalized human MECs transduced with control R780 vector or R780:DEK (a Dek expression construct). This 3D human cell culture model closely mimics the structure of the mammary gland, with a spherical layer of polarized epithelium and a hollow lumen. DEK overexpression resulted in a hyperplastic phenotype, as evident by the enlarged acinar structures and filled lumens (**Figure 2c**, top and center panels). Wnt signaling is known to regulate cell and tissue polarity. Therefore, we assessed polarity in this 3D context by staining for the apical surface marker, GM130. DEK-overexpressing acini contained more cells with deregulated polarity, as indicated by aberrant localization of GM130 (**Figure 2c**, top panel, white arrows and graph below). When the acini were cultured in a mix of Matrigel and collagen to promote invasive phenotypes, DEK overexpression led to the production of invasive laminin-V-negative multicellular structures, which were not observed in control cells (**Figure 2c**, bottom panel and data not shown). (Initiating PI)

Figure 2. Ron and DEK cooperate in human breast cancer to promote disease progression. (a) DEK is a downstream target gene of activated Ron signaling in T47D human breast cancer cells. T47D cells were treated with HGFL to activate Ron signaling and DEK expression was analyzed by quantitative RT–PCR. Expression was compared with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and normalized to expression in untreated cells. For the 24 h time point, P=0.07 and significance was calculated with a one-tailed unpaired t-test. (b) DEK protein levels are elevated following HGFL-mediated activation of Ron signaling. T47D cells were treated with HGFL for the time periods shown and whole-cell lysates were analyzed by western blotting. (c) DEK overexpression in MCF10A cells induces phenotypes of advanced breast cancer in 3D culture, including increased acinar size, cells present within the lumen and cellular invasion. MCF10A cells transduced with R780 or R780:DEK (hDek) were grown in Matrigel 3D culture (top and middle panels) to test for morphology or Matrigel–collagen 3D cultures to test for invasion (bottom panel). Immunofluorescence was performed on day 20 of culture and visualized with a Zeiss LSM510 scanning confocal microscope; the white size bar represents 10 μm. Phase-contrast images are also shown in the middle and bottom panels, and black arrows indicate invading cells in the bottom panel. The Golgi marker GM130 is used to mark cell apical–basal polarity, and white arrows highlight cells with deregulated polarity. The percentage of cells with mislocalized GM130 per acinar structure is depicted below the images, which was calculated from triplicate experiments. (d) DEK and Ron expression predict β-catenin expression levels in primary human breast cancer. Serial sections from two tissue microarrays of patient-derived breast infiltrating ductal carcinomas were stained by immunohistochemistry for Dek, Ron and β-catenin expression. Correlation was analyzed by χ2 testing. (e and f) Combined DEK and Ron expression predict disease relapse in a cohort of 1000 unmedicated patients (P=0.00018) (e) and progression to distant metastatic disease in 1609 patients treated with systemic therapies (P=0.00098) (f). A meta-analysis of patient and gene expression data archived in Kaplan–Meier Plotter (http://www.kmplot.com) was performed to generate Kaplan–Meier curves. The numbers under each graph represent the number of patients at each time point.

b HGFL (100ng/ml)

hrs	0	2	4	6	24	48
DEK						
Actin						
	1.0	1.24	1.77	2.78	6.10	4.99

T47D

d

	High Ron and/or High DEK	Low Ron and DEK
High β-catenin 13/28 (46%)	12/13 **	1/13
Low β-catenin 15/28 (54%)	7/15	8/15

e Relapse-Free Survival in untreated patients

HR = 1.52 (1.22 - 1.9) logrank P = 0.00018

Expression low / high RON/DEK

Number at risk
low 693 540 326 92 12 0
high 307 193 111 38 6 1

f Distant Metastasis-Free Survival in treated patients

HR = 1.41 (1.15 - 1.72) logrank P = 0.00098

Expression low / high RON/DEK

Number at risk
low 766 600 345 108 17 1 0
high 863 557 245 57 10 1 0

Ron and DEK expression cooperate to promote β-catenin activity and disease progression in human primary breast cancers

Immunohistochemical staining of serial sections from two breast cancer microarrays was performed. Analyses were limited to infiltrating ductal carcinomas, and we determined that 54% (15 of 28) of samples expressed high levels of DEK, whereas 46% (13 of 28) highly expressed Ron. By themselves, the expression of each protein was suggestive of high β-catenin levels, indicating pathway activation (data not shown). When combined, 74% (31 of 42) of breast cancers expressed high levels of Ron and/ or DEK, which also was highly predictive of strong β-catenin staining (**Figure 2d**). Finally, an in silico meta-analysis of patient and gene expression data archived in Kaplan–Meier Plotter (http://www.kmplot.com) was performed to assess the impact of DEK and Ron expression on patient survival. In each case, high Dek expression was very predictive of poor patient outcome and the strength of the association was enhanced by adding Ron expression (data not shown). Taken together, high DEK and Ron expression were predictive of early relapse in breast cancer patients that did not receive systemic endocrine therapy or chemotherapy (**Figure 2e**). The combined markers also correlated with a higher risk for developing distant metastases in breast cancer patients treated with systemic therapies (**Figure 2f**) and with poor postprogression survival in all patients (data not shown). Our results lead to a proposed model whereby elevated DEK expression results in the enhanced transcription and secretion of Wnt ligands that can promote cellular proliferation through a paracrine mechanism that is driven by

β-catenin signaling (**Figure 3**). Furthermore, Ron receptor tyrosine kinase activation is a novel mechanism for DEK upregulation and, independently, can promote β-catenin stabilization and subsequent transcriptional activity [**Figure 3**, (4)]. This combination of events converging upon the β-catenin pathway can then contribute to tumor growth and metastasis. (Initiating and Partnering PIs)


Figure 3. Model. Ron stimulates Dek expression for sustained β-catenin signaling. Ron can directly activate intracellular β-catenin, while Dek induces expression of Wnt ligands, which are secreted into the tumor microenvironment to amplify β-catenin activity by autocrine and paracrine mechanisms.

Task 2

The goal of Task 2 as outlined in the approved Statement of Work was to examine the utility of targeting Ron and Dek on beta-catenin activation and breast cancer growth. As mentioned in the prior progress report, we performed a characterization of the 1716HSV DEK knockdown vectors and found that these constructs were not able to efficiently target DEK. We are continuing to work with Virttu Biologics to design the next generation of 1716DEKsh constructs that will robustly silence DEK expression but have yet to obtain substantive results in this area. While the 1716HSV platform remains the a viable strategy to therapeutically target the DEK oncogene as the protein is not yet amenable to small molecule treatment and a crystal structure not available, we are currently examining alternatives for DEK targeting. During the no cost extension period, we intend to test any new available oncolytic virus to target DEK as well as initiate alternatives to target DEK through the use of RNA nanoparticle technology. We look forward to testing these approaches as well as seek new alternatives to accomplish this goal. An additional goal for the no cost extension period to perform additional experiments as outlined in Task 1b in the Statement of Work that attempts to target the Ron-DEK axis utilizing orthotopic transplantation models of Ron and Dek modified cells in the context of chemotherapeutic responses. The focus of pending studies will identify strategies to target this aggressive pathway in breast cancer. (Initiating PI)

KEY RESEARCH ACCOMPLISHMENTS

- Staffing in place to support continuation of the project
- Generated compound mice containing mammary specific Ron overexpression (MMTV-Ron) combined with DEK hetero and homozygosity.
- Initiated procedures to successfully genotype mice from breeding colonies.
- Defined the impact of Dek loss in Ron overexpressing mammary tumors though temporal analysis of tumor kinetics, incidence, and growth.
- Identified by western blot analysis, immunohistochemistry and qRT-PCR the alteration in Wnt ligand induction and in beta-catenin activation in Dek proficient and depleted cells.
- Performed testing of the first generation of Dek targeted oncolytic viruses and determined that these constructs do not effectively mediate Dek suppression.
- Identification of metastatic and invasive capabilities of Dek overexpression.

- Further data on Dek as an important downstream Ron effector in human and murine breast cancer.
- Determined that Dek and Ron expression cooperate to promote beta-catenin activity and that expression of both genes are highly correlated with breast cancer patient survival.
- Found that high DEK and Ron expression are predictive of early relapse in breast cancer and correlated with a higher risk for developing distant metastases.

PRODUCTS

Gene Targeted Animals:
Generated breeding colonies to obtain MMTV-Ron mice that are wild type (+/+), heterozygous (+/-) and deficient (-/-) for Dek.

Cell lines:
Generated several mammary tumor cell lines from MMTV-Ron mice with and without Dek deficiency.

Research Opportunities:
Sasha Ruiz, Graduate student, 2013-present
Eric Smith, Graduate student, 2012-present
Purnima Wagh, PhD, 2012-2013; Graduated with her PhD in December of 2013
Nancy Benight, PhD, 2012-present
Juana Serrano-Lopez, visiting scientist, 2013-present
Nicholas Pease, research assistant, 2013-present
Lisa Privette, PhD, 2013-present
Nathan Head, Undergraduate Summer Student Research Project , May 2014-August 2014
Jessica Mace, Undergraduate Research, University of Cincinnati, May 2014-current

Manuscripts under preparation/submitted/published:
The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE, Wells SI.
Oncogene. 2014 Jun 23. doi: 10.1038/onc.2014.173. [Epub ahead of print] PMID: 24954505   PMCID: Pending

Presentations:
Privette Vinnedge LM, Benight NM, Maag L, Waltz SE, Wells SI. Expression of the DEK oncogene predicts the response of breast cancer cells to chemotherapy. Mechanisms and Models of Cancer meeting. Cold Spring Harbor Laboratory, NY. August 12-16, 2014 (poster presentation).

Privette Vinnedge LM, Wagh PK, Serrano-Lopez J, Waltz SE, Wells SI. The Dek Oncogene Drives Breast Cancer Progression and Chemotherapeutic Resistance. Tenth Anniversary Interdisciplinary Women's Health Research Symposium, National Institutes of Health, Bethesda, MD. October 24, 2013 (oral presentation).

Privette Vinnedge LM. Playing with a full DEK: The DEK oncogene drives breast cancer progression through b-catenin signaling. Invited guest lecture, Wright State University. May 21, 2013 (oral presentation).

Smith EA, Krumpelbeck EF, Kavanaugh GM, Gole B, Wiesmüller L, Meetei AR, Kappes F, Wells SI. The RAD-ical DEK Oncogene in Chemoresistance. International DNA Tumor Virus Meeting, Madison WI. July 26, 2014 (oral presentation).

Smith EA, Krumpelbeck EF, Kavanaugh GM, Wells SI. The RAD-ical DEK Oncogene. University of Cincinnati MSTP Spring Retreat, University of Cincinnati College of Medicine, Cincinnati, OH; Mar 24, 2014 (oral presentation).

Head NB, Benight N, Waltz SE. The Ron Receptor as a Promoter of Therapeutic Resistance in Breast Cancer. Summer Undergraduate Research Fellowship Capstone Meeting. August 1, 2014 (poster presentation).

Benight NM, Wagh PK, Waltz SE. HGFL-dependent Ron signaling is critical for mammary tumorigenesis. Frontiers in Basic Cancer Research. September 20, 2013 (poster presentation).

Benight NM, Wagh PK, Waltz SE. HGFL-dependent Ron signaling is critical for mammary tumorigenesis. Meet the Breast Cancer Team: Innovative Research and Patient Care, University of Cincinnati and UC Health, Cincinnati OH. November 9, 2013 (poster presentation).

Benight NM and Waltz SE. The Role of HGFL in Breast Cancer Development and Metastasis. Cancer Therapeutics Data Critique and Journal Club. November 5, 2013 (oral presentation).

Ruiz-Torres SJ, Gurusamy D, and Waltz SE. "Hepatocyte Growth Factor-Like protein is a positive regulator of early mammary gland ductal morphogenesis". Meet the Breast Cancer Team: Innovative Research and Patient Care Conference, University of Cincinnati and UC Health, Cincinnati, OH, November 9, 2013 (poster presentation).

Ruiz-Torres SJ, Gurusamy D, and Waltz SE. Hepatocyte Growth Factor-Like protein is a positive regulator of early mammary gland ductal morphogenesis. 2013 Graduate Student Research Forum (GSRF). Cincinnati, OH, October 15, 2013 (poster presentation).

Ruiz-Torres SJ, Gurusamy D, and Waltz SE. Hepatocyte Growth Factor-Like protein is a positive regulator of early mammary gland ductal morphogenesis. Meet the Breast Cancer Team: Innovative Research and Patient Care Conference. Cincinnati, OH, November 9, 2013 (poster presentation).

Ruiz-Torres SJ, Gurusamy D, and Waltz SE. Hepatocyte Growth Factor-Like protein is a positive regulator of early mammary gland ductal morphogenesis. 2013 Graduate Student Research Forum (GSRF). Cincinnati, OH, October 15, 2013 (poster presentation).

IMPACT & CONCLUSIONS

- Our data provide the first direct demonstration that the oncogene Dek is a downstream target of Ron receptor signaling in breast cancer.
- The Dek upregulation observed in Ron expressing breast tumors provides a growth and migratory/invasive phenotype to the breast cancer cells.
- Dek loss in MMTV-Ron mice significantly reduces the time to tumor initiation and is associated with decreased breast cancer cell proliferation.
- Dek expression controls key molecules involved in Wnt signaling in breast tumors and in breast cancer cell lines.
- Oncolytic virus containing a shRNA for Dek was produced.
- Initial testing of the shDek oncolytic virus has shown that the shDek oncolytic virus is similarily effective compared to the oncolytic virus alone. Further testing has shown that the shRNA does not effectively knockdown Dek.
- The next generation of Dek targeting oncolytic vectors is being planned.

PARTICIPANTS AND OTHER COLLABORATING ORGANIZATIONS/SPECIAL REPORTING REQUIREMENTS

Participants
Susan Waltz, PI, No change

Susanne Wells, PI, No change
Sasha J. Ruiz-Torres, Graduate Student, No change
Nancy Benight, Postdoctoral Fellow, No change
Eric Smith, Graduate Student, No change
Lisa Privette Vinnedge, Assistant Professor, No change
Nathan Head, Undergraduate Student, 2 calendar months, Mr. Head performed titration experiments for cisplatnin resistance of Ron modulated cell lines.   Funded by NIH supported ASPET Program.
Jessica Mace, Undergraduate Student, 2 calendar months, Ms. Mace performed histology work for this project. Ms. Mace received undergraduate research credit from the University for this experience.
Purnima Wagh, Graduate Student, Graduated with a PhD in December of 2013.
Juana Serrano-Lopez, Visiting Scientist, No change
Nicholas Pease, Research Assistant, No change

Reporting Requirements
A duplicative report is being submitted for this collaborative award.

REFERENCES

1.   Privette Vinnedge, L.M., Benight, N.M., Wagh, P.K., Pease, N.A., Nashu, M.A., Serrano-Lopez, J., Adams, A.K., Cancelas, J.A., Waltz, S.E., and Wells, S.I. 2014. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. *Oncogene*.
2.   Privette Vinnedge, L.M., McClaine, R., Wagh, P.K., Wikenheiser-Brokamp, K.A., Waltz, S.E., and Wells, S.I. 2011. The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer. *Oncogene* 30:2741-2752.
3.   Wu, B., Crampton, S.P., and Hughes, C.C. 2007. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. *Immunity* 26:227-239.
4.   Wagh, P.K., Gray, J.K., Zinser, G.M., Vasiliauskas, J., James, L., Monga, S.P., and Waltz, S.E. 2011. beta-Catenin is required for Ron receptor-induced mammary tumorigenesis. *Oncogene* 30:3694-3704.

APPENDICES

The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE, Wells SI.
Oncogene. 2014 Jun 23. doi: 10.1038/onc.2014.173. [Epub ahead of print]   PMID: 24954505   PMCID: Pending

npg

ORIGINAL ARTICLE

The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers

LM Privette Vinnedge[1], NM Benight[2], PK Wagh[3], NA Pease[1], MA Nashu[2], J Serrano-Lopez[4,5], AK Adams[1], JA Cancelas[4,6], SE Waltz[2,7] and SI Wells[1]

Disease progression and recurrence are major barriers to survival for breast cancer patients. Understanding the etiology of recurrent or metastatic breast cancer and underlying mechanisms is critical for the development of new treatments and improved survival. Here, we report that two commonly overexpressed breast cancer oncogenes, Ron (Recepteur d'Origine Nantaise) and DEK, cooperate to promote advanced disease through multipronged effects on β-catenin signaling. The Ron receptor is commonly activated in breast cancers, and Ron overexpression in human disease stimulates β-catenin nuclear translocation and is an independent predictor of metastatic dissemination. Dek is a chromatin-associated oncogene whose expression has been linked to cancer through multiple mechanisms, including β-catenin activity. We demonstrate here that Dek is a downstream target of Ron receptor activation in murine and human models. The absence of Dek in the MMTV-Ron mouse model led to a significant delay in tumor development, characterized by decreased cell proliferation, diminished metastasis and fewer cells expressing mammary cancer stem cell markers. Dek complementation of cell lines established from this model was sufficient to promote cellular growth and invasion. Mechanistically, Dek expression stimulated the production and secretion of Wnt ligands to sustain an autocrine/paracrine canonical β-catenin signaling loop. Finally, we show that Dek overexpression promotes tumorigenic phenotypes in immortalized human mammary epithelial MCF10A cells and, in the context of Ron receptor activation, correlates with disease recurrence and metastasis in patients. Overall, our studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/β-catenin signaling.

Oncogene advance online publication, 23 June 2014; doi:10.1038/onc.2014.173

INTRODUCTION

Despite high survival rates for early-stage breast cancer, it is still the second leading cause of cancer-related deaths in the United States. This is because of the poor survival associated with late-stage, invasive disease and treatment-resistant breast cancers. Most new diagnoses are invasive cancers, which have poor survival rates.[1] Therefore, it is important to identify proteins that predict disease relapse or progression and that may also be therapeutic targets.

Several reports identified the Ron (Recepteur d'Origine Nantaise) receptor tyrosine kinase, a MET family member, as an important driver of breast tumorigenesis. Ron is minimally expressed in normal breast epithelium, but is highly expressed in approximately 50% of human breast cancers.[2] Ron activation from overexpression has been implicated in driving metastasis and correlates with poor prognosis.[2,3] Little is known about the molecular mechanisms through which Ron promotes breast cancer proliferation and metastases. Recently, it was reported that Ron activation leads to c-abl activation and proliferating cell nuclear antigen (PCNA) localization to chromatin to drive proliferation.[4] Ron also activates numerous cytoplasmic signaling

pathways, including Ras/MAPK, PI3K and β-catenin through direct phosphorylation, and regulates many downstream targets.[5–7] Here, we identify a novel nuclear effector of Ron activation, the DEK oncogene.

DEK is a unique protein with no known paralogs or enzymatic function.[8] It is predominantly chromatin bound and has been implicated in numerous processes including DNA repair, replication, transcriptional regulation and mRNA splicing.[8–14] The role of DEK in these processes is unclear, but may be due to its histone chaperone and Su(var) activities that regulate chromatin organization.[15,16] Many reports have shown that DEK can function as a cofactor for transcriptional regulation; however, DEK can both repress and activate transcription of target genes. For example, several reports have shown that DEK inhibits NF-κB/p65/RelA transcriptional activity,[17–19] decreases hTERT expression in leukemias[20] and can interact with poly (ADP-ribose) polymerase 1 (PARP1) to restrict the accessibility of the transcription complexes to chromatin.[21] Other reports indicate that DEK can also activate transcription by interacting with several transcription factors, including C/EBPα during myeloid differentiation,[22] nuclear ecdysone receptor in *Drosophila*[16] and AP-2α in rat liver and human cell lines.[10] Interestingly, DEK can also be secreted and is

[1]Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; [2]Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, OH, USA; [3]Department of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; [4]Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; [5]IMIBIC/UCO/University Hospital Reina Sofia, Cordoba, Spain; [6]Hoxworth Blood Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA and [7]Department of Research, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH, USA. Correspondence: Dr SI Wells or Dr LM Privette Vinnedge, Division of Oncology, Cincinnati Children's Hospital Medical Center, MLC 7013, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
E-mails: Susanne.Wells@cchmc.org or Lisa.Privette@cchmc.org
Received 26 November 2013; revised 18 April 2014; accepted 9 May 2014

an autoantigen in patients with juvenile idiopathic arthritis and was detected in the urine of patients with bladder cancer.[23–25] Macrophages can secrete DEK and neighboring cells can internalize it in a heparan sulfate-dependent process where it then completes its normal nuclear functions.[26]

DEK is transcriptionally upregulated in several solid tumors and was initially discovered as a CAN (NUP214) fusion gene in acute myeloid leukemia.[27–32] Transcriptional upregulation is accomplished via the Rb/E2F pathway and steroid hormone signaling, but 6p22.3 amplifications have been noted.[32–36] Cell culture, murine chemical carcinogenesis and xenograft tumor models indicate that DEK overexpression promotes proliferation.[29,30,32,37] There are several possible molecular mechanisms for this DEK-mediated proliferation, including upregulation of ΔNp63α and, in the case of the DEK-NUP214 fusion, mTORC1 activity.[29,30,37,38] Additional cell culture models implicate DEK in promoting cell invasion, in part due to β-catenin signaling.[29,32] However, the oncogenic functions of DEK have not been tested in vivo using genetically engineered mouse models. Furthermore, the molecular mechanisms through which full-length DEK drives proliferation and β-catenin signaling in breast cancer are unknown.

Here, we crossed Dek[−/−] mice with the MMTV-Ron murine breast cancer model to determine the requirement for Dek during breast cancer initiation and progression. We report that Dek is a downstream target of activated Ron signaling such that the MMTV-Ron model recapitulates DEK overexpression observed in some human breast cancers. The loss of Dek delayed tumor growth and decreased lung metastases. We generated Dek-proficient and -deficient breast cancer cell lines from the

murine tumors and found that reconstitution of Dek in knockout cells rescued cellular growth and invasive phenotypes in vitro. Importantly, we present new evidence that Dek-expressing cells can drive the proliferation of cells within the microenvironment through stimulated expression and secretion of Wnt4, Wnt7b and Wnt10b. Finally, we translate the observed oncogenic DEK activities, and the combination of Ron and DEK activation, to human breast cancer using three-dimensional (3D) cell culture models, tissue microarrays and patient survival data. We propose that DEK drives tumor growth and progression, particularly in the context of Ron receptor activation, via Wnt ligand production and subsequent activation of the β-catenin pathway.

RESULTS

The MMTV-Ron mouse model recapitulates DEK overexpression observed in breast cancer

The MMTV-Ron mouse is an established malignant breast cancer model wherein Ron expression is controlled by the MMTV mammary-specific promoter. Mice begin to develop tumors at 4–5 months of age with a high prevalence of lung metastases.[3] Western blot analysis of primary tumors from MMTV-Ron mice compared with normal murine mammary gland tissue revealed Dek upregulation in tumors (Figure 1a). Furthermore, western blot analysis of mammary epithelial cells (MECs) isolated from a non-transgenic (WT) and a non-tumor-bearing MMTV-Ron transgenic mouse also revealed Dek upregulation in the transgenic mammary gland (Figure 1b). To determine whether Ron activation specifically induced Dek expression, R7 mammary tumor cells previously


Figure 1. Dek expression is upregulated in the MMTV-Ron murine breast cancer model. (**a**) Dek is overexpressed in MMTV-Ron mammary gland tumors compared with normal mammary gland tissue as determined by western blot analysis. Actin is used as a loading control. (**b**) Dek is overexpressed in primary 'MECs' from pre-neoplastic MMTV-Ron mammary glands compared with non-transgenic mouse mammary glands, as determined by western blot analysis. Cytokeratin 14 (CK14) is used as a loading control, demonstrating equal amounts of epithelial cells in the lysates. Relative expression as determined by densitometry is shown. (**c**) Dek is transcriptionally upregulated in R7 cells, a cell line generated from an MMTV-Ron tumor, following Ron receptor activation with HGFL. Quantitative reverse transcription–PCR was performed at the given time points after stimulation with HGFL. Dek expression is normalized to actin and relative to the 0 h time point. (**d**) Dek protein levels are elevated following HGFL stimulation of the Ron receptor in R7 cells. Western blot analysis was performed on whole-cell lysates and analyzed for Dek and actin expression. WT, wild type.

isolated from an MMTV-Ron tumor were treated with the Ron ligand, hepatocyte growth factor-like protein (HGFL; Supplementary Figure S1).[3,39] Ron activation with HGFL resulted in increased *Dek* mRNA and protein (Figures 1c and d), indicating that *Dek* is a downstream target of Ron. These findings show that the MMTV-Ron (*Ron^{tg}*) model is appropriate for studying the role of Dek overexpression during tumorigenesis *in vivo*.

The absence of Dek delays tumor development owing to diminished proliferation

The Dek-knockout allele was introduced into the MMTV-Ron mouse to generate Dek-deficient (*Ron^{tg}Dek^{-/-}*) mice. *Ron^{tg}Dek^{-/-}* mice were significantly delayed in palpable tumor development compared with Dek-proficient *Ron^{tg}Dek^{+/+}* controls (Figure 2a). There were no significant differences in tumor incidence or in the number of tumors that eventually developed (Figure 2a and data not shown). We previously published that DEK depletion by short hairpin RNA (shRNA) in MDA-MB-468 human breast cancer cells results in smaller xenograft tumors associated with decreased tumor proliferation.[29] To determine if decreased proliferation accounted for the delayed tumor onset in *Ron^{tg}Dek^{-/-}* mammary glands, preneoplastic glands were analyzed for bromodeoxyuridine (BrdU) incorporation as a proliferation marker. Glands from *Ron^{tg}Dek^{-/-}* mice had substantially fewer BrdU-positive cells when compared with control mice (Figure 2b). To assess directly the necessity of Dek for tumor cell growth, cell lines were established from tumors isolated from independent mice. Dek expression was subsequently decreased by shRNA (Deksh) in *Ron^{tg}Dek^{+/+}*-derived tumors, and murine Dek (mDek) was exogenously expressed in cell lines generated from *Ron^{tg}Dek^{-/-}* tumors (see western blot analysis depicted as insets in Figure 2c). In all cell lines tested, depleting Dek in *Ron^{tg}Dek^{+/+}* cell lines decreased growth rates (Figure 2c, top row), whereas complementing Dek expression in *Ron^{tg}Dek^{-/-}* cell lines increased growth rates (Figure 2c, bottom row). In addition, a trend was observed wherein cells derived from *Ron^{tg}Dek^{-/-}* tumors grew more slowly than cells from *Ron^{tg}Dek^{+/+}* tumors, based on comparisons of vector-transduced *Ron^{tg}Dek^{+/+}* 'NTsh' and *Ron^{tg}Dek^{-/-}* 'R780' control cells (Figure 2c, black lines).

Dek expression positively correlates with BCSC phenotypes

We have previously shown that DEK expression correlates with the size of the breast cancer stem cell (BCSC) population in human MCF7 cells.[29] To test this finding in murine samples, we analyzed first passage cancer cells isolated from the *Ron^{tg}Dek^{+/+}* and *Ron^{tg}Dek^{-/-}* tumors for known cell surface murine BCSC markers by flow cytometry (Lin$^-$/CD49f$^+$/CD24$^+$/CD44^{low}).[40–42] We detected significantly fewer Lin$^-$/CD49f$^+$/CD24$^+$/CD44^{low} cells in *Ron^{tg}Dek^{-/-}* tumors compared with *Ron^{tg}Dek^{+/+}* samples (Figure 2d). To further our analysis, we plated *Ron^{tg}Dek^{+/+}* R7 NTsh/Deksh cells and four *Ron^{tg}Dek^{-/-}* lines with empty vector or mDek for mammosphere formation. Although there were no differences in mammosphere numbers, a significant positive correlation between Dek expression and sphere volume was observed, which is in agreement with the notion that Dek drives proliferation (Figure 2e). There was also a positive correlation between Dek expression and the percentage of side population cells. Dek depletion in *Ron^{tg}Dek^{+/+}* R7 cells lowered the percentage of side population cells, whereas reconstitution of Dek in a *Ron^{tg}Dek^{-/-}* RD147 cells increased the percentage of side population cells (Supplementary Figure S2A). Interestingly, there also was a trend toward diminished tumor formation when cells derived from *Ron^{tg}Dek^{-/-}* tumors were injected into the mammary fat pad (Supplementary Figure S2B). Taken together, the data indicate that Dek contributes to tumor initiation and growth in the transgenic mouse model through enhanced proliferation and promotes BCSC phenotypes.

Dek expression promotes cancer metastasis *in vivo* and *in vitro*

Previous reports using *in vitro* transwell assays suggest that DEK conferred invasive potential to breast cancer cells via a β-catenin-dependent mechanism.[29] However, an association between DEK expression and metastatic events *in vivo* had not yet been investigated. We examined metastases to the lungs and liver from *Ron^{tg}Dek^{-/-}* and *Ron^{tg}Dek^{+/+}* mice. Of the mice examined, 100% of *Ron^{tg}Dek^{+/+}* and 83% of *Ron^{tg}Dek^{-/-}* mice developed liver metastases. All *Ron^{tg}* mice examined had lung metastases, but *Ron^{tg}Dek^{+/+}* mice had more than double the number of lung metastases per animal when compared with *Ron^{tg}Dek^{-/-}* mice (Figure 3a). Lung metastases were positive for cytokeratin 5 staining, indicating they were epithelial in origin (Supplementary Figure S3A). One potential mechanism of metastasis is through the expression of matrix metalloproteases (MMPs), including the Wnt targets MMP2 and MMP9.[43] Primary and xenograft tumors and the cell lines showed no correlation between DEK expression and MMP2 or MMP9 expression (Supplementary Figures S3B and C). To test invasion *in vitro*, Dek-proficient and -deficient cell lines (described above) were analyzed using Matrigel transwell invasion assays. Dek expression enhanced the invasive potential in all cell lines tested (Figure 3b, see Figures 2c and 4a for Dek expression).

Dek drives proliferation through Wnt signaling

We previously showed that DEK expression correlated with β-catenin activity in human breast cancer cell lines and that this activity drove cell invasion in Matrigel transwell assays.[29] However, the mechanism for this regulation was unknown. Preliminary data from a quantitative reverse transcription–PCR array was used, wherein we screened for expression differences of over 80 Wnt signaling pathway members in *Dek^{+/+}* versus *Dek^{-/-}* mouse embryonic fibroblasts (MEF)[13] to select relevant Wnt/β-catenin pathway members for further analysis (Supplementary Figures S4A and B). We identified Wnt4, Wnt7b and Wnt10b to be differentially regulated by Dek expression (Figure 4a). Deksh in R7 cells resulted in decreased Wnt expression, whereas complementation of four *Ron^{tg}Dek^{-/-}* cell lines with mDek resulted in increased Wnt expression. Wnt10b, a canonical Wnt ligand, was pursued owing to its strong association with breast cancer development and proliferation.[44,45] The observed differences in *Wnt10b* mRNA correlated with differences in secreted protein levels detected in conditioned media (Figure 4b). The upregulation of Wnts also correlated with increased β-catenin transcriptional activity as determined by the TOP/FOP luciferase reporter assay (Figure 4c), a finding that agrees with our previous work with MEFs.[29] We also observed upregulation of the pro-proliferative Wnt/β-catenin target gene cyclin D1 and increased protein levels of other Wnt pathway members (Figure 4d and Supplementary Figure S4C). To determine if Wnt signaling promoted Dek-mediated proliferation, green fluorescent protein (GFP)(−) parental RD147 cells (*Ron^{tg}Dek^{-/-}*) were cocultured in equal numbers with GFP(+) cells transduced with either R780 vector or R780:mDek. BrdU incorporation as a measure of proliferation was then assessed by flow cytometric anlaysis of the GFP(−) Dek-deficient cells. Coculturing *Ron^{tg}Dek^{-/-}* RD147 parental cells with cells expressing mDek resulted in enhanced proliferation of the Dek-deficient cells. Treatment with IWP-2, a Porcupine inhibitor that prevents Wnt secretion, significantly diminished the pro-proliferative effects of elevated Dek and Wnt expression, decreasing the proliferation of parental Dek-deficient RD147 cells close to control levels (Figure 4e).

Dek expression correlates with tumor growth, Wnt10b expression and β-catenin activity *in vivo*

To determine if Dek regulates Wnt10b expression *in vivo*, *Ron^{tg}Dek^{+/+}* R7 cells transduced with NTsh or Deksh constructs were injected into the mammary gland to generate orthotopic tumors in female nude

4

mice. Tumors from Deksh cells grew significantly slower than tumors from control (NTsh) cells (Figure 5a). Immunohistochemical staining demonstrated significantly diminished Wnt10b and activated β-catenin levels in Deksh tumors, suggesting attenuated β-catenin activity (Figure 5b, quantified in Figure 5C). Taken together, this suggests that Dek-mediated tumor growth is associated with Wnt expression and subsequent β-catenin activation.

Ron receptor activation increases DEK expression and DEK overexpression confers tumorigenic phenotypes to immortalized human MECs

We treated T47D cells with HGFL to determine if Ron activation also upregulates *DEK* in human breast cancer cell lines. *DEK* mRNA was upregulated within hours of HGFL stimulation, resulting in elevated protein levels (Figures 6a and b). This further supports

the hypothesis that DEK overexpression in breast cancer cell lines is induced by Ron receptor activation.

To determine if DEK overexpression promoted tumorigenic phenotypes in human mammary cells similar to that observed in the mouse, we used 3D cultures of MCF10A immortalized human MECs transduced with control R780 vector or R780:DEK.[29] This 3D human cell culture model closely mimics the structure of the mammary gland, with a spherical layer of polarized epithelium and a hollow lumen.[46] DEK overexpression resulted in a hyperplastic phenotype, as evident by the enlarged acinar structures and filled lumens (Figure 6c, top and center panels). Wnt signaling is known to regulate cell and tissue polarity.[47–49] Therefore, we assessed polarity in this 3D context by staining for the apical surface marker, GM130. DEK-overexpressing acini contained more cells with deregulated polarity, as indicated by aberrant localization of GM130 (Figure 6c, top panel, white arrows and graph below). When the acini were cultured in a mix of Matrigel and collagen to promote invasive phenotypes, DEK overexpression led to the production of invasive laminin-V-negative multicellular structures, which were not observed in control cells (Figure 6c, bottom panel and data not shown).

Ron and DEK expression cooperate to promote β-catenin activity and disease progression in human primary breast cancers

Immunohistochemical staining of serial sections from two breast cancer microarrays was performed. Analyses were limited to infiltrating ductal carcinomas, and we determined that 54% (15 of 28) of samples expressed high levels of DEK, whereas 46% (13 of 28) highly expressed Ron. By themselves, the expression of each protein was suggestive of high β-catenin levels, indicating pathway activation (Supplementary Figure S5A). When combined, 74% (31 of 42) of breast cancers expressed high levels of Ron and/or DEK, which also was highly predictive of strong β-catenin staining (Figure 6d).

Finally, an in silico meta-analysis of patient and gene expression data archived in Kaplan–Meier Plotter (http://www.kmplot.com) was performed to assess the impact of DEK and Ron expression on patient survival. In each case, high Dek expression was very predictive of poor patient outcome and the strength of the association was enhanced by adding Ron expression (Supplementary Figures S5B and D). Taken together, high DEK and Ron expression were predictive of early relapse in breast cancer patients that did not receive systemic endocrine therapy or chemotherapy (Figure 6e). The combined markers also correlated with a higher risk for developing distant metastases in breast cancer patients treated with systemic therapies (Figure 6f) and with poor postprogression survival in all patients (Supplementary Figure S5D).

Our results lead to a proposed model whereby elevated DEK expression results in the enhanced transcription and secretion of Wnt ligands that can promote cellular proliferation through a paracrine mechanism that is driven by β-catenin signaling (Figure 7). Furthermore, Ron receptor tyrosine kinase activation is a novel mechanism for DEK upregulation and, independently, can promote β-catenin stabilization and subsequent transcriptional activity (Figure 7).[6] This combination of events converging upon the β-catenin pathway can then contribute to tumor growth and metastasis.

DISCUSSION

We previously published that $Dek^{-/-}$ mice developed fewer papillomas and were delayed in papilloma formation in a chemically induced model of skin cancer.[30] We provide the first report of the role of the DEK oncogene in a genetic murine model of malignant breast cancer. In this report, the absence of DEK did not prevent tumor formation and the mice ultimately developed similar numbers of tumors. However, $Dek^{-/-}$ mice show delayed tumor initiation and have significantly fewer proliferating cells in preneoplastic mammary glands. This is supported by the finding that proliferation could be rescued by exogenous Dek expression in independently generated cell lines from these $Dek^{-/-}$ tumors. Importantly, we also have observed the relationship between Dek expression and cell growth in an esophageal cancer cell line derived from a murine 4NQO chemical carcinogenesis model, indicating that this correlation is not limited to the MMTV-Ron model (Supplementary Figure S6A).[37]

In human cancers, RNA interference-mediated DEK loss has been reported to cause apoptosis or senescence, as well as decreased proliferation in the surviving cells.[29,32,34,35,50] Factors that determine the cellular response to DEK depletion are poorly understood, although p53, MCL-1 and p65 functionality have been implicated.[18,27,50] The fact that Dek-knockout mice are viable seems to be at odds with the findings in human cells. However, differentiated human keratinocytes are largely resistant to apoptosis and senescence after DEK depletion by shRNA expression. This suggests that the differentiated, largely quiescent tissues in the mouse may not be markedlly affected by the loss of Dek under controlled stress and pathogen-free conditions. It is of interest that MEFs from $Dek^{-/-}$ mice are slightly less proliferative with elevated numbers of senescent cells under normal culture conditions compared with $Dek^{+/+}$ MEFs, possibly because of increased baseline levels of DNA damage. However, knockout MEFs are significantly more senescent and apoptotic when stressed, such as treatment with etoposide.[13] Therefore, we hypothesize that Dek/DEK expression promotes proliferation through Wnt signaling and ΔNp63 levels; however, the loss of Dek causes decreased mitogenic signaling as well as DNA damage, which, when exacerbated by environmental stress and/or genetic background, leads to a marked apoptotic or senescent response.[13,29,37]

Figure 2. Dek promotes tumor growth and increases cell proliferation in vivo and in vitro. (**a**) $Ron^{tg}Dek^{-/-}$ (MMTV-Ron and $Dek^{-/-}$) mice exhibit delayed tumor onset compared with $Ron^{tg}Dek^{+/+}$ mice. Time to tumor detection for $Ron^{tg}Dek^{-/-}$ mice was 232.1 ± 10.27 days ($N = 14$) compared with 193.6 ± 4.206 days ($N = 23$; mean ± s.e.m.; ***$P < 0.0001$, log-rank test). (**b**) Preneoplastic mammary glands from $Ron^{tg}Dek^{+/+}$ mice ($24.16 \pm 2.728\%$, $N = 11$) are more proliferative than glands from $Ron^{tg}Dek^{-/-}$ mice ($9.401 \pm 1.562\%$, $N = 8$; **$P = 0.0006$, as determined by unpaired two-tailed t-test). Mice were intraperitoneally injected with BrdU before being killed. Immunohistochemistry for BrdU incorporation was performed on preneoplastic glands. Representative images are shown. Results are quantified in the graph on the right as the percentage of BrdU-positive cells in the tissue section. (**c**) Dek expression levels positively correlate with cellular growth rate in Ron^{tg} tumor-derived cell lines. Cell lines were generated from three $Ron^{tg}Dek^{+/+}$ and three $Ron^{tg}Dek^{-/-}$ tumors from independent mice. A Dek shRNA (Deksh) was introduced into $Ron^{tg}Dek^{+/+}$ cells to decrease Dek expression or an mDek overexpression construct was retrovirally transduced into $Ron^{tg}Dek^{-/-}$ to complement the loss of Dek. Western blots in the inset show changes in Dek expression (D) with α-tubulin (T) as a loading control. Cells were counted over the time periods shown for each cell line. (**d**) Tumors from $Ron^{tg}Dek^{-/-}$ mice ($N = 4$) have fewer cells with BCSC cell surface markers compared with $Ron^{tg}Dek^{+/+}$ tumors ($N = 3$). Flow cytometry was used to quantify the percentage of Lin⁻/CD49f⁺/CD24⁺/CD44^low cells. (**e**) Dek expression promotes the growth of mammospheres. $Ron^{tg}Dek^{+/+}$ cell line (R7) transduced with Deksh ('+Deksh') or NTsh control, and $Ron^{tg}Dek^{-/-}$ cell lines (RD147, RD219, RD238 and RD271) transduced with an mDek construct ('+mDek') or control R780 vector were plated in non-adherent mammosphere cultures and measured after 9 days to calculate volume. Data are presented as fold change compared with control (NTsh or R780) spheres from triplicate experiments.

Figure 3. Dek expression supports breast cancer metastasis *in vivo* and *in vitro*. (**a**) $Ron^{tg}Dek^{+/+}$ mice have a greater metastatic lung tumor burden than $Ron^{tg}Dek^{-/-}$. Lungs were harvested from six $Ron^{tg}Dek^{-/-}$ and five $Ron^{tg}Dek^{+/+}$ mice with similar primary tumor volumes for the largest tumor and serial sections were microscopically analyzed for tumor metastases. Total tumor burden from all lung sections in wild-type mice was 18.38 ± 1.754 compared with 8.183 ± 1.661 in knockout mice ($P = 0.0023$, unpaired two-tailed *t*-test). The average number of lung metastases per mouse is quantified and a representative hematoxylin and eosin staining from each genotype is depicted below. Black arrows highlight metastatic tumors within the lungs. (**b**) Dek expression correlates with cellular invasion *in vitro*. $Ron^{tg}Dek^{+/+}$ cell lines (R7 and RD258) transduced with Deksh ('+Deksh') or NTsh control, and $Ron^{tg}Dek^{-/-}$ cell lines (RD147, RD219, RD238 and RD271) transduced with an mDek construct ('+mDek') or control R780 vector were subjected to Matrigel transwell assays. Data are represented as fold change compared with the respective control for each cell line (NTsh or R780) for triplicate experiments. Significance was calculated with a one-tailed unpaired *t*-test.

Molecular mechanism(s) through which DEK promotes proliferation are not well understood. Cell-free assays and immunoprecipitation experiments suggest that DEK may facilitate DNA replication.[9,14] DEK also promotes proliferation through ΔNp63 protein activities, but the effectors of this pathway remain unexplored.[29,51,52] Our previous studies have shown that DEK expression correlates with proliferation by BrdU incorporation in xenograft tumors and organotypic raft cultures of the skin, but the molecular drivers behind this finding were not identified.[29,52] We also published previously that DEK expression correlates with β-catenin activity in human breast cancer[29] and we have observed this correlation in primary cells from human head and neck squamous cell carcinomas (Supplementary Figures S6B and C), thus supporting broad importance for the observed DEK–β-catenin signaling axis in solid tumors. Here, we connect our previous findings and identify a molecular mechanism through which DEK can promote proliferation and β-catenin activity— through the transcriptional regulation of Wnt4, Wnt7b and Wnt10b. These three Wnts have been implicated in promoting oncogenic phenotypes and proliferation. In particular, Wnt10b is a known canonical Wnt ligand that prompts the stabilization and activation of β-catenin and can promote proliferation in triple-negative breast cancer.[53] Wnt10b is an early marker of the mammary lineage, a crucial driver of mammary gland development, and supports mammary stem cell proliferation as suggested by regulation of mammary stem cell marker Sca-1.[44,54,55] Wnt10b also is overexpressed in breast cancer cell lines and can induce transformation; furthermore, MMTV-Wnt10b mice develop hyperplasia and excessive ductal branching, phenotypes that precede the development of adenocarcinomas.[44–46] Wnt4 expression also supports basal mammary epithelial stem cell proliferation, promotes mammary gland development and branching during pregnancy, and is overexpressed in breast cancer cell lines, although it is not transforming by itself.[56–58] Wnt7b is a non-canonical ligand whose upregulation has been observed in other murine breast cancer models and was shown to promote epithelial proliferation in the lung.[59–63] All three of these Wnts are known to be expressed in human breast tissue and were reported to be overexpressed in breast cancer.[64] Additional work will be required to determine whether Dek-mediated transcription of Wnt ligands is due to the role of DEK in chromatin reorganization or as a transcriptional cofactor.[15,16] Furthermore, we report DEK-mediated positive regulation of β-catenin in both breast cancer and head and neck squamous cell carcinomas, which suggests that this oncogenic mechanism may be relevant for several types of solid tumors.

In coculturing experiments, we found that Dek-expressing cells could promote the proliferation of neighboring Dek-deficient cells through a paracrine signaling mechanism. Importantly, inhibiting the secretion of Wnt ligands with the Porcupine inhibitor, IWP-2, markedly reduced this pro-proliferative effect. This suggests that Dek-expressing cells promote the proliferation of cells within the tumor microenvironment. It is also noteworthy that IWP-2 did not entirely eliminate the pro-proliferative effect observed in coculture experiments, indicating that Dek-expressing cells may be secreting other growth factors that drive the proliferation of neighboring cells. Interestingly, this may explain why DEK is not expressed in every cell in primary invasive breast adenocarcinomas; only a fraction of the cells may need to express DEK to drive proliferation of the entire tumor.[29] In addition, Wnt10b and Wnt4 drive mammary stem cell proliferation and Wnt/β-catenin activity is a well-known regulator of the normal and cancer stem cell populations. Future studies will determine if the positive effect of Dek expression on the size of the mouse and human breast cancer stem cell population is due to Wnt expression and β-catenin activation driving cancer stem cell proliferation.

This report highlights for the first time a role of Dek expression in an *in vivo* model of cancer metastasis. Although Dek loss did not

Figure 4. Dek expression stimulates Wnt ligand production to drive proliferation via a paracrine mechanism. (**a**) Dek expression positively regulates Wnt4, Wnt7b and Wnt10b transcription. Dek knockdown by Deksh2 in R7 cells downregulates Wnt expression, whereas Dek complementation in $Ron^{tg}Dek^{-/-}$ cell lines upregulates Wnt ligand expression. *Dek* and *Wnt* gene expression were analyzed by quantitative RT–PCR in replicate experiments. Data is presented as fold change compared to respective controls (NTsh or R780). (**b**) Dek expression correlates with the secretion of Wnt10b. Conditioned media from $Ron^{tg}Dek^{+/+}$ R7 NTsh and Deksh2 cells and $Ron^{tg}Dek^{-/-}$ RD147 R780 and mDek cells was concentrated and analyzed by western blot analysis for Wnt10b. (**c**) Complementation of Dek expression in $Ron^{tg}Dek^{-/-}$ RD147 increases β-catenin transcriptional activity. RD147 cells transduced with R780 and mDek (R780:mDek) were transfected with TOPflash and FOPflash luciferase reporter assay constructs. Luciferase expression represents β-catenin transcriptional activity. (**d**) Dek complementation in knockout cells results in increased expression of Wnt/β-catenin target genes, including cyclin D1. Western blot analysis of whole-cell lysates from $Ron^{tg}Dek^{-/-}$ RD147 R780 and R780:mDek cells was performed using the antibodies shown. Relative expression as determined by densitometry is shown below each blot. (**e**) Dek-induced Wnt secretion increases the proliferation of neighboring Dek-deficient cancer cells. GFP − parental $Ron^{tg}Dek^{-/-}$ RD147 cells were cocultured with GFP+ RD147 R780 or R780:mDek cells. BrdU incorporation was then analyzed by flow cytometry in GFP − cells as a measure of cell proliferation. Cells were also treated with IWP-2, a Wnt secretion inhibitor, before analysis. Inhibiting Wnt secretion partially rescues the proproliferative effect of neighboring Dek-expressing cells. The western blot inset depicts levels of secreted Wnt10b in conditioned media in untreated and IWP-2-treated RD147 R780 or R780:mDek GFP+ cells. The images depicted are from different blots for Wnt10b. NS, nonsiginificant. Significance was calculated with a two-tailed unpaired *t*-test.

prevent metastases, it significantly decreased metastatic tumor burden in the lungs and resulted in reduced liver metastases. We saw no correlation between Dek expression and the expression of Wnt target genes *MMP2* and *MMP9*; however, this does not exclude other potential mechanisms. A possible alternative is that Dek may also regulate the expression of non-canonical Wnt ligands, such as Wnt5a and Wnt7b, which can activate the Rho/Rac planar cell polarity pathway to direct cell motility.[65,66] Interestingly, DEK loss was recently shown to regulate negatively Rho signaling in non-small-cell lung cancer.[67] In addition to lung metastases, we observed that Dek expression significantly promoted invasion in transwell assays in multiple murine breast

cancer cell lines and in primary head and neck squamous cell carcinoma cells (Supplementary Figure S6D), which agrees with previous reports in human breast and lung cancer and indicates that DEK-mediated invasion is relevant to several cancer types.[29,32] Of interest, breast patient data associated high *DEK* expression with an increased risk for distant metastasis in previously node-negative patients. The overall finding is that while Dek is not required for metastasis, it promotes cellular invasion and the growth of metastatic tumors. Interestingly, Wnt signaling has also been implicated in cellular motility and cancer metastasis. In canine breast adenocarcinomas, Wnt7b was found to be upregulated in metastatic cell lines isolated from the lungs

Figure 5. Dek depletion delays tumor growth and results in decreased Wnt10b and activated β-catenin expression *in vivo*. (**a**) Dek depletion (Deksh) in *Ron^{tg}Dek$^{+/+}$* R7 cells delays tumor growth. *Ron^{tg}Dek$^{+/+}$* R7 NTsh and Deksh cells were injected into inguinal mammary fat pads in nude mice and monitored for tumor growth. (**b**) Dek depletion inhibits Wnt/β-catenin activity in tumors. Immunohistochemical staining for Dek, Wnt10b and activated β-catenin was performed on tumors from R7 NTsh and Deksh cells. (**c**) Quantification of data presented in (**b**). The relative staining intensity of activated β-catenin ($N = 5$ tumors each) and Wnt10b ($N = 4$ tumors each) was quantified as the product of staining intensity and percentage of positively staining cells. Data are represented as fold change. Activated β-catenin scores were (22.13 ± 5.80) for R7 NTsh and (14.26 ± 3.68) for R7 Deksh tumors and were determined based on positive staining nuclei, while Wnt10b scores were (16.84 ± 3.33) for R7 NTsh and (7.79 ± 1.87) for R7 Deksh. Significance was calculated by comparing matched tumors harvested from the same mouse with a two-tailed paired *t*-test.

compared with isogenic primary tumor cell lines.[68] Wnt10b and Wnt4 are potent regulators of mammary gland branching, which leads us to hypothesize that they may be involved in DEK-mediated promotion of cancer cell motility when overexpressed in tumors.[44,58] We have already reported that DEK knockdown decreased invasion *in vitro* in human breast cancer cells, and invasion was rescued by the expression of a constitutively active β-catenin construct.[29] This report, combined with our previous work, suggests that DEK-mediated activation of Wnt/β-catenin signaling, at least in part, promotes proliferation, invasion and altered cell polarity.

Finally, we show that elevated DEK expression, partially due to Ron activation, is relevant to human breast cancer. Exogenous expression of DEK in immortalized MCF10A cells grown in 3D culture induces tumorigenic phenotypes reminiscent of invasive adenocarcinomas. Furthermore, DEK expression can be induced by Ron receptor activation with HGFL. This combination of Ron and DEK expression are highly predictive of strong β-catenin staining by immunohistochemistry, disease relapse in patients not treated with systemic therapies and distant metastases in patients who have received systemic therapies. This indicates that Ron and DEK cooperate to promote breast cancer in mice and humans. Although the signaling events regulated by Ron and DEK are not fully understood, both are known to activate Wnt/β-catenin signaling. Both also have been implicated in promoting the activity of other oncogenic signaling cascades linked to cancer progression, including the roles of DEK in regulating the function of p53 family members and DNA repair, and of Ron in promoting the activation of PI3K-Akt and Ras/MAPK pathways.[13,29,52,69] Combined, we propose that Ron and DEK cooperate to drive breast cancer progression and relapse. Developing novel therapeutics that target these proteins could significantly slow tumor growth and limit the risk of metastasis or disease relapse,

and may be particularly effective when combined with traditional therapies.

MATERIALS AND METHODS
Cell culture
T47D and MCF10A cells were obtained from the American Type Culture Collection and grown under recommended conditions. R7 cells are a murine mammary tumor line from a previously described MMTV-Ron mouse.[3,39] We established the remaining cell lines from mammary tumors that developed in the MMTV-Ron (*Ron^{tg}*) mice used in this study. Cell lines R7, RD258 and RD272 were generated from *Ron^{tg}Dek$^{+/+}$* tumors and cell lines RD147, RD219, RD238 and RD271 were from *Ron^{tg}Dek$^{-/-}$* tumors. Briefly, tumor fragments were digested in 2 mg/ml collagenase in DMEM: F12 media for 2 h at 37 °C and then washed six times in phosphate-buffered saline with differential centrifugation to enrich for epithelial cells. Resulting organoids were grown in DMEM:F12 media supplemented with 10% fetal bovine serum, 1% penicillin–streptomycin, 1% Fungizone, 2 mM L-glutamine, 5 µg/ml gentamicin, 10 ng/ml epidermal growth factor, 10 µg/ml human recombinant insulin, 5 µg/ml transferrin and 50 µM sodium selenite and then passaged at least 20 times.

Cells were treated with 100 ng/ml recombinant HGFL protein (MSP, Cys 672 Ala; R&D Systems, Minneapolis, MN, USA) for the indicated time points. To inhibit Wnt secretion, cells were treated with 10 µM IWP-2 (Sigma-Aldrich, St Louis, MO, USA) for 24 h before analysis. For growth curves, cells were plated at equal density of 50 000 cells per well in 6-well plates, trypsinized and counted in triplicate using a hemocytometer.

3D MCF10A cultures were generated and stained by immunofluorescence as described previously.[46] MCF10A cells retrovirally transduced with R780 and R780:DEK also were described previously.[29] Acinar structures were photographed at day 4 for invasive cultures (Matrigel and collagen) at ×100 total magnification. Immunofluorescence was performed on day 20 of culture and visualized with a Zeiss LSM510 scanning confocal microscope (Carl Zeiss Microscopy GmbH, Jena, Germany).

Cells were transduced with retroviral constructs, R780 and R780:mDek containing an mDek construct, as described previously and sorted based

Figure 6. Ron and DEK cooperate in human breast cancer to promote disease progression. (**a**) DEK is a downstream target gene of activated Ron signaling in T47D human breast cancer cells. T47D cells were treated with HGFL to activate Ron signaling and DEK expression was analyzed by quantitative RT–PCR. Expression was compared with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and normalized to expression in untreated cells. For the 24 h time point, $P = 0.07$ and significance was calculated with a one-tailed unpaired t-test. (**b**) DEK protein levels are elevated following HGFL-mediated activation of Ron signaling. T47D cells were treated with HGFL for the time periods shown and whole-cell lysates were analyzed by western blotting. (**c**) DEK overexpression in MCF10A cells induces phenotypes of advanced breast cancer in 3D culture, including increased acinar size, cells present within the lumen and cellular invasion. MCF10A cells transduced with R780 or R780:DEK (hDek) were grown in Matrigel 3D culture (top and middle panels) to test for morphology or Matrigel–collagen 3D cultures to test for invasion (bottom panel). Immunofluorescence was performed on day 20 of culture and visualized with a Zeiss LSM510 scanning confocal microscope; the white size bar represents 10 μm. Phase-contrast images are also shown in the middle and bottom panels, and black arrows indicate invading cells in the bottom panel. The Golgi marker GM130 is used to mark cell apical–basal polarity, and white arrows highlight cells with deregulated polarity. The percentage of cells with mislocalized GM130 per acinar structure is depicted below the images, which was calculated from triplicate experiments. (**d**) DEK and Ron expression predict β-catenin expression levels in primary human breast cancer. Serial sections from two tissue microarrays of patient-derived breast infiltrating ductal carcinomas were stained by immunohistochemistry for Dek, Ron and β-catenin expression. Correlation was analyzed by χ^2 testing. (**e** and **f**) Combined DEK and Ron expression predict disease relapse in a cohort of 1000 unmedicated patients ($P = 0.00018$) (**e**) and progression to distant metastatic disease in 1609 patients treated with systemic therapies ($P = 0.00098$) (**f**). A meta-analysis of patient and gene expression data archived in Kaplan–Meier Plotter (http://www.kmplot.com) was performed to generate Kaplan–Meier curves. The numbers under each graph represent the number of patients at each time point.

Figure 7. Model. Ron stimulates Dek expression for sustained β-catenin signaling. Ron can directly activate intracellular β-catenin, while Dek induces expression of Wnt ligands, which are secreted into the tumor microenvironment to amplify β-catenin activity by autocrine and paracrine mechanisms.

on GFP expression[30] or transduced with the lentiviral pLKO.1 constructs (Deksh represents pLKO.1_DEK832 in the Mission library (Sigma-Aldrich) and was previously described as 'DEKsh2'[29]) and selected in 4 µg/ml puromycin. NTsh is a non-targeting control. All cell populations were analyzed within six passages of selection.

PCR
Total mRNA was isolated using Trizol extraction, and then reverse transcribed using the Quantitect kit (Qiagen, Valencia, CA, USA). cDNA was amplified with SYBR Green PCR master mix using an ABI-7500 quantitative PCR machine (Applied Biosystems, Carlsbad, CA, USA) and analyzed using the ΔΔCt method. The following forward (F) and reverse (R) primer pairs were used at a concentration of 0.4 ng/µl each (primers labeled with 'm' were used for murine cells and those with an 'h' denote human sequence): mDek F (5′-AACGTGGGTCAGTTCAGTGGC-3′); mDek R (5′-TTCGCTGTTCACGCCTGACCT-3′); mActin F (5′-GATATCGCTGCGCTGGTC GTC-3′); mActin R (5′-ACCATCACACCCTGGTGCCTAG-3′); mWnt4 F (5′-AGC AGGTGTGGCCTTTGCAGTGAC-3′); mWnt4 R (5′-CGTTGTTGTGAAGATTCATG AGTGCC-3′); mWnt7b F (5′-AGTGGATCTTTTACGTGTTTCTCTG-3′); mWnt7b R (5′-CTGGTTGTAGTAGCCTTGCTTCTC-3′); mWnt10b F (5′-AGAAGTTCTC TCGGGATTTCTTG-3′); mWnt10b R (5′-CAAAGTAAACCAGCTCTCCAG-3′); hGAPDH F (5′-GGTCTCCTCTGACTTCAACA-3′); hGAPDH R (5-ATACCAGGAA ATGAGCTTGA-3′); hDEK F (5′-TGTTAAGAAAGCAGATAGCAGCACC-3′); hDEK R (5′-ATTAAAGGTTCATCATCTGAACTATCCTC-3′).

Western blotting
Total protein was extracted with RIPA buffer and subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis before being transferred to a PVDF membrane. Blots were probed with specific antibodies to DEK (BD Bioscience, San Jose, CA, USA); Ron (C-20), Wnt10b (H70) and cyclin D1 (72-13G) (Santa Cruz, Dallas, TX, USA); α-tubulin (Sigma Aldrich), actin C4 (gift from James Lessard, Cincinnati Children's Hospital, Cincinnati, OH, USA); axin 2, MMP2 and MMP9 (Abcam, Cambridge, MA, USA), cytokeratin 14 (Covance, Princeton, NJ, USA) and GSK3β, phospho-ERK1/2, total ERK1/2 and TCF1 (Cell Signaling, Danvers, MA, USA). Protein from primary MECs was collected from 18-week-old nulliparous, non-tumor-bearing $Dek^{+/+}$ females by isolating the cells through collagenase digestion and differential centrifugation as described above immediately before the addition of lysis buffer. For secreted proteins, 3×10^6 cells were plated on 10 cm dishes in complete media for 2 h and then cells were washed in phosphate-buffered saline and overlayed with media containing 1% FBS for 24 h. Six milliliters of conditioned media were collected from each cell line and concentrated to 100 µl using Amicon Ultra-4 centrifugal filters with Ultracel-3 membrane (Millipore, Billerica, MA, USA) and then 2 µl was diluted into 18 µl of serum-free media

before western blotting. Western blots were analyzed by densitometry using Image J (National Institutes of Health, Washington, DC, USA).[70]

Mice
$Dek^{-/-}$ mice (gift from Gerard Grosveld, St Jude Children's Research Hospital, Memphis, TN, USA) were previously described and were backcrossed into an FVB/N background, which is the same background as the MMTV-Ron model.[3,30] MMTV-Ron male mice were bred to $Dek^{+/-}$ females then MMTV-Ron, $Dek^{+/-}$ male progeny were bred to $Dek^{+/-}$ females to generate $Ron^{tg}Dek^{+/+}$ and $Ron^{tg}Dek^{-/-}$ females.[3,30] Females were continuously bred starting at 6 weeks old and then monitored weekly for tumor development. Tumors were measured with digital calipers and volume was calculated as $((\pi/6) \times L \times W^2)$.[71,72] Two hours before being killed, the mice were intraperitoneally injected with 600 µg of BrdU. At necropsy, the mice were weighed and the tumors were excised, measured, weighed, fixed in 4% paraformaldehyde and embedded in paraffin. Portions of one tumor per mouse were used to generate novel $Ron^{tg}Dek^{+/+}$ and $Ron^{tg}Dek^{-/-}$ cell lines (see above). Lungs and livers were examined for metastases as described previously.[73]

For allograft tumor studies, 5×10^5 cells suspended in phosphate-buffered saline were injected into the inguinal mammary fat pads of nulliparous, 12-week-old female athymic nude mice. Tumors were measured and collected as described above. Usage and handling of mice was performed with the approval of the Cincinnati Children's Institutional Animal Care and Use Committee. All mice were housed in specific pathogen-free housing with *ad libitum* access to food and water.

Immunohistochemistry
Paraformaldehyde-fixed and paraffin-embedded tissues were cut into 5 µm sections, subjected to sodium citrate antigen retrieval and stained using the M.O.M. Peroxidase Kit (Vector Labs, Burlingame, CA, USA) and 3,3′-diaminobenzidine. The following antibodies were used: DEK (1:60; BD Biosciences), BrdU (1:100; Molecular Probes, Invitrogen, Grand Island, NY, USA), Wnt10b (H70) (1:50; Santa Cruz), MMP2 and MMP9 (1:100 and 1:200, respectively; Santa Cruz), cytokeratin 5 (1:200; Abcam) or activated β-catenin (8E7) (1:100; Millipore). Samples were counterstained with 0.1% Nuclear Fast Red (Poly Scientific, Bay Shore, NY, USA) and preserved with Permount (Fisher Scientific, Pittsburgh, PA, USA). Tissue microarrays were purchased from Imgenex (San Diego, CA, USA; CBA2 and CBB2) for correlations of Ron, DEK and β-catenin expression in human tissues and scored as described previously.[6] For tumors generated from R7 NTsh and Deksh cells, staining intensity was quantified by the Threshold tool on Image J. The threshold for each section was set and normalized to each section's respective total area of tissue as seen at ×200 total magnification. Scores were calculated by multiplying the intensity score by the percentage of positive staining cells. The total number of cells counted per section ranged from 122 to 357. For activated β-catenin staining, cells were considered positive if the nucleus showed 3,3′-diaminobenzidine staining.

Flow cytometry
All flow cytometry was performed on a FACSCanto cytometer (BD Biosciences). Mouse cell surface marker staining was determined with the Lineage Cocktail Kit and streptavidin-APC-Cy7 in combination with CD44-PE, CD49f-FITC and CD24-APC antibodies (all from BD Biosciences). For coculturing experiments, 2×10^5 cells of each genotype were plated in 60 mm dishes, grown overnight and then treated with 100 µM BrdU for 35 min before staining with the APC BrdU Kit (BD Biosciences). BrdU incorporation was measured in GFP⁻ and GFP⁺ cells.

Mammosphere culture
Mammosphere cultures were performed and photographed as described previously.[29] Image J was used to measure the radius and calculated sphere volume as $(4/3)\pi \times r^3$ for each mammosphere in triplicate experiments.

Invasion assay
Matrigel transwell assays were used to determine invasive potential *in vitro* (BD Biosciences). Cells were seeded at low density in supplement-free media and complete media were placed into the bottom chamber as a chemoattractant. After 20 h, invading cells were methanol fixed and

stained with Giemsa and then manually counted. The data are represented as fold change relative to vector controls.

TOP/FOP assay
Cells were transfected with 10 ng pRL-TK and 500 ng of pSUPER(8x) TOPFlash or pSUPER(8x)FOPFlash using TransIT-LT1 reagent (Mirus Bio, Madison, WI, USA) and then assayed with the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Plasmids were a gift from Dr Aaron Zorn (Cincinnati Children's Hospital). Data are presented as the ratio of relative light units of TOPFlash to FOPFlash from triplicate experiments.

Kaplan–Meier curves
Kaplan–Meier plots were generated with KM plotter for Breast Cancer, 2014 version (http://www.kmplot.com), which is a publicly available online database of archived gene expression and patient survival data.[74] We used the multigene classifier and mean expression of probes, 200934_at (DEK) and 205455_at (Ron), and did not restrict analysis by subtype. We analyzed relapse-free survival in systemically untreated patients and distant metastasis-free survival in patients treated with endocrine therapies or chemotherapies.

Statistics
Mouse tumor-free survival was analyzed using the log-rank test. The χ^2 test was used to identify correlations with protein expression using tissue microarrays. For all other experiments, an unpaired two-tailed Student's t-test was used, unless otherwise noted. Error bars depict standard error of data collected from at least three experiments. Significance was set at $P < 0.05$. One asterisk (*) indicates $P < 0.05$, two asterisks (**) indicate $P < 0.01$ and three asterisks (***) indicate $P < 0.001$.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1 ACS. Breast Cancer Facts & Figures 2011–2012. American Cancer Society: Atlanta, GA, USA, 2011.
2 Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998; 16: 2927–2933.
3 Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA et al. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 2006; 66: 11967–11974.
4 Zhao H, Chen MS, Lo YH, Waltz SE, Wang J, Ho PC et al. The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. Oncogene 2013; 33: 1429–1437.
5 Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003; 3: 31–40.
6 Wagh PK, Gray JK, Zinser GM, Vasiliauskas J, James L, Monga SP et al. Beta-catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene 2011; 30: 3694–3704.
7 Leonis MA, Thobe MN, Waltz SE. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Fut Oncol 2007; 3: 441–448.
8 Privette Vinnedge LM, Kappes F, Nassar N, Wells SI. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle 2013; 12: 51–66.
9 Alexiadis V, Waldmann T, Andersen J, Mann M, Knippers R, Gruss C. The protein encoded by the proto-oncogene DEK changes the topology of chromatin and reduces the efficiency of DNA replication in a chromatin-specific manner. Genes Dev 2000; 14: 1308–1312.
10 Campillos M, Garcia MA, Valdivieso F, Vazquez J. Transcriptional activation by AP-2alpha is modulated by the oncogene DEK. Nucleic Acids Res 2003; 31: 1571–1575.
11 McGarvey T, Rosonina E, McCracken S, Li Q, Arnaout R, Mientjes E et al. The acute myeloid leukemia-associated protein, DEK, forms a splicing-dependent interaction with exon–product complexes. J Cell Biol 2000; 150: 309–320.
12 Soares LM, Zanier K, Mackereth C, Sattler M, Valcarcel J. Intron removal requires proofreading of U2AF/3' splice site recognition by DEK. Science 2006; 312: 1961–1965.
13 Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 2011; 39: 7465–7476.
14 Lossaint G, Larroque M, Ribeyre C, Bec N, Larroque C, Decaillet C et al. FANCD2 binds MCM proteins and controls replisome function upon activation of S phase checkpoint signaling. Mol Cell 2013; 51: 678–690.
15 Kappes F, Waldmann T, Mathew V, Yu J, Zhang L, Khodadoust MS et al. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. Genes Dev 2011; 25: 673–678.
16 Sawatsubashi S, Murata T, Lim J, Fujiki R, Ito S, Suzuki E et al. A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. Genes Dev 2010; 24: 159–170.
17 Kim DW, Kim JY, Choi S, Rhee S, Hahn Y, Seo SB. Transcriptional regulation of 1-cys peroxiredoxin by the proto-oncogene protein DEK. Mol Med Rep 2010; 3: 877–881.
18 Liu K, Feng T, Liu J, Zhong M, Zhang S. Silencing of the DEK gene induces apoptosis and senescence in CaSki cervical carcinoma cells via the up-regulation of NF-kappaB p65. Biosci Rep 2012; 32: 323–332.
19 Sammons M, Wan SS, Vogel NL, Mientjes EJ, Grosveld G, Ashburner BP. Negative regulation of the RelA/p65 transactivation function by the product of the DEK proto-oncogene. J Biol Chem 2006; 281: 26802–26812.
20 Karam M, Thenoz M, Capraro V, Robin JP, Pinatel C, Lancon A et al. Chromatin Redistribution of the DEK oncoprotein represses hTERT transcription in leukemias. Neoplasia 2014; 16: 21–30.
21 Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. Nat Struct Mol Biol 2007; 14: 548–555.
22 Koleva RI, Ficarro SB, Radomska HS, Carrasco-Alfonso MJ, Alberta JA, Webber JT et al. C/EBPalpha and DEK coordinately regulate myeloid differentiation. Blood 2012; 119: 4878–4888.
23 Mor-Vaknin N, Kappes F, Dick AE, Legendre M, Damoc C, Teitz-Tennenbaum S et al. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. Arthritis Rheum 2011; 63: 556–567.
24 Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS et al. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006; 26: 9484–9496.
25 Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer 2011; 11: 234.
26 Saha AK, Kappes F, Mundade A, Deutzmann A, Rosmarin DM, Legendre M et al. Intercellular trafficking of the nuclear oncoprotein DEK. Proc Natl Acad Sci USA 2013; 110: 6847–6852.
27 Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS et al. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009; 69: 6405–6413.
28 Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999; 59: 4990–4996.
29 Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates beta-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene 2011; 30: 2741–2752.
30 Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA et al. Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009; 69: 1792–1799.
31 von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992; 12: 1687–1697.
32 Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 2010; 29: 4671–4681.
33 Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006; 5: 1202–1207.

34 Privette Vinnedge LM, Ho SM, Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. *PLoS ONE* 2012; **7**: e46985.

35 Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K *et al.* The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. *J Virol* 2005; **79**: 14309–14317.

36 Evans AJ, Gallie BL, Jewett MA, Pond GR, Vandezande K, Underwood J *et al.* Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. *Am J Pathol* 2004; **164**: 285–293.

37 Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ *et al.* DEK promotes HPV-positive and -negative head and neck cancer cell proliferation. *Oncogene* (e-pub ahead of print 10 March 2014; doi:10.1038/onc.2014.15).

38 Sanden C, Ageberg M, Petersson J, Lennartsson A, Gullberg U. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR. *BMC Cancer* 2013; **13**: 440.

39 McClaine RJ, Marshall AM, Wagh PK, Waltz SE. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. *Neoplasia* 2010; **12**: 650–658.

40 Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D *et al.* Purification and unique properties of mammary epithelial stem cells. *Nature* 2006; **439**: 993–997.

41 Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML *et al.* Generation of a functional mammary gland from a single stem cell. *Nature* 2006; **439**: 84–88.

42 Ma J, Lanza DG, Guest I, Uk-Lim C, Glinskii A, Glinsky G *et al.* Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. *Tumour Biol* 2012; **33**: 1983–1996.

43 Wu B, Crampton SP, Hughes CC. Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. *Immunity* 2007; **26**: 227–239.

44 Lane TF, Leder P. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. *Oncogene* 1997; **15**: 2133–2144.

45 Miyoshi K, Rosner A, Nozawa M, Byrd C, Morgan F, Landesman-Bollag E *et al.* Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. *Oncogene* 2002; **21**: 5548–5556.

46 Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods* 2003; **30**: 256–268.

47 Habib SJ, Chen BC, Tsai FC, Anastassiadis K, Meyer T, Betzig E *et al.* A localized Wnt signal orients asymmetric stem cell division *in vitro*. *Science* 2013; **339**: 1445–1448.

48 Karner C, Wharton KA, Carroll TJ. Apical–basal polarity, Wnt signaling and vertebrate organogenesis. *Semin Cell Dev Biol* 2006; **17**: 214–222.

49 Gao B. Wnt regulation of planar cell polarity (PCP). *Curr Top Dev Biol* 2012; **101**: 263–295.

50 Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. *Mol Cell Biol* 2006; **26**: 7506–7519.

51 Moll UM, Slade N. P63 and p73: roles in development and tumor formation. *Mol Cancer Res* 2004; **2**: 371–386.

52 Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ *et al.* DEK proto-oncogene expression interferes with the normal epithelial differentiation program. *Am J Pathol* 2009; **174**: 71–81.

53 Wend P, Runke S, Wend K, Anchondo B, Yesayan M, Jardon M *et al.* WNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. *EMBO Mol Med* 2013; **5**: 264–279.

54 Veltmaat JM, Van Veelen W, Thiery JP, Bellusci S. Identification of the mammary line in mouse by Wnt10b expression. *Dev Dyn* 2004; **229**: 349–356.

55 Miranda-Carboni GA, Krum SA, Yee K, Nava M, Deng QE, Pervin S *et al.* A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. *Genes Dev* 2008; **22**: 3121–3134.

56 Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. *Oncol Rep* 2006; **15**: 701–707.

57 Meier-Abt F, Milani E, Roloff T, Brinkhaus H, Duss S, Meyer DS *et al.* Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. *Breast Cancer Res* 2013; **15**: R36.

58 Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone–Wnt connection. *Genes Dev* 2000; **14**: 889–894.

59 Shimizu H, Julius MA, Giarre M, Zheng Z, Brown AM, Kitajewski J. Transformation by Wnt family proteins correlates with regulation of beta-catenin. *Cell Growth Differ* 1997; **8**: 1349–1358.

60 Huguet EL, McMahon JA, McMahon AP, Bicknell R, Harris AL. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. *Cancer Res* 1994; **54**: 2615–2621.

61 Kuorelahti A, Rulli S, Huhtaniemi I, Poutanen M. Human chorionic gonadotropin (hCG) upregulates wnt5b and wnt7b in the mammary gland, and hCGbeta transgenic female mice present with mammary gland tumors exhibiting characteristics of the Wnt/beta-catenin pathway activation. *Endocrinology* 2007; **148**: 3694–3703.

62 Yin YJ, Katz V, Salah Z, Maoz M, Cohen I, Uziely B *et al.* Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization. *Cancer Res* 2006; **66**: 5224–5233.

63 Rajagopal J, Carroll TJ, Guseh JS, Bores SA, Blank LJ, Anderson WJ *et al.* Wnt7b stimulates embryonic lung growth by coordinately increasing the replication of epithelium and mesenchyme. *Development* 2008; **135**: 1625–1634.

64 Howe LR, Brown AM. Wnt signaling and breast cancer. *Cancer Biol Ther* 2004; **3**: 36–41.

65 Florian MC, Nattamai KJ, Dorr K, Marka G, Uberle B, Vas V *et al.* A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing. *Nature* 2013; **503**: 392–396.

66 Schlessinger K, Hall A, Tolwinski N. Wnt signaling pathways meet Rho GTPases. *Genes Dev* 2009; **23**: 265–277.

67 Wang J, Sun L, Yang M, Luo W, Gao Y, Liu Z *et al.* DEK depletion negatively regulates Rho/ROCK/MLC pathway in non-small cell lung cancer. *J Histochem Cytochem* 2013; **61**: 510–521.

68 Krol M, Polanska J, Pawlowski KM, Turowski P, Skierski J, Majewska A *et al.* Transcriptomic signature of cell lines isolated from canine mammary adenocarcinoma metastases to lungs. *J Appl Genet* 2010; **51**: 37–50.

69 Wang MH, Zhang R, Zhou YQ, Yao HP. Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. *J Biomed Res* 2013; **27**: 345–356.

70 Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods* 2012; **9**: 671–675.

71 Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. *J Surg Oncol* 1986; **31**: 229–234.

72 Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. *Cancer Chemother Pharmacol* 1989; **24**: 148–154.

73 Peace BE, Toney-Earley K, Collins MH, Waltz SE. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. *Cancer Res* 2005; **65**: 1285–1293.

74 Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q *et al.* An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res Treat* 2010; **123**: 725–731.

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)